SCHEMBL3260035

SCHEMBL3260035

O=Cc1cc(C(F)(F)F)cnc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
KMT2A Q03164 3/20 0.42
ALDH1A1 P00352 9/20 0.41
POLB P06746 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 2/20 0.39
PLAU P00749 1/20 0.39
HTT P42858 4/20 0.39
MAPT P10636 2/20 0.39
GAA P10253 2/20 0.39
GLA P06280 1/20 0.39
HPGD P15428 1/20 0.39
MEN1 O00255 2/20 0.38
MAPK1 P28482 1/20 0.38
JAK2 O60674 1/20 0.38
HSP90AA1 P07900 1/20 0.38
PKM P14618 1/20 0.38
MC4R P32245 1/20 0.38
RAB9A P51151 1/20 0.38
CCR6 P51684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20576368 0.79 ALOX5AP (0.40) LMNAKMT2AALDH1A1POLBSMN1; SMN2
SCHEMBL4515539 0.78 KMT2A (0.39) LMNAKMT2AALDH1A1POLBSMN1; SMN2
SCHEMBL29955340 0.78 ALOX5AP (0.42) LMNAKMT2AALDH1A1POLBSMN1; SMN2
SCHEMBL8789256 0.77 PLAU (0.43) LMNAKMT2AALDH1A1POLBSMN1; SMN2
SCHEMBL4511815 0.77 HPGD (0.52) KMT2AALDH1A1SMN1; SMN2KDM4EPLAU
SCHEMBL4511823 0.77 HPGD (0.52) KMT2AALDH1A1SMN1; SMN2KDM4EPLAU
SCHEMBL29954582 0.75 ERN1 (0.39) KMT2AALDH1A1SMN1; SMN2KDM4EPLAU
SCHEMBL2119952 0.75 ERN1 (0.39) KMT2AALDH1A1SMN1; SMN2KDM4EPLAU
SCHEMBL1675500 0.74 KMT2A (0.51) LMNAKMT2AALDH1A1POLBSMN1; SMN2
SCHEMBL6076848 0.74 ERN1 (0.46) LMNAKMT2AALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688785-A1 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 Beone Medicines I GmbH (CH) 2026-02-11 EP disclosed
WO-2024199255-A1 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-d] PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 BEIGENE SWITZERLAND GMBH (CH) 2024-10-03 WO disclosed
US-20240166664-A1 TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2024-05-23 US disclosed
CN-111344287-B Novel substituted biaryl compounds as indoleamine 2, 3-dioxygenase (IDO) inhibitors 默沙东有限责任公司 2023-12-19 CN disclosed
EP-4289845-A1 TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2023-12-13 EP disclosed
EP-4289845-A1 TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2023-12-13 EP disclosed
CN-116724044-A Tri-heterocyclic compound, preparation method and application thereof 上海湃隆生物科技有限公司 2023-09-08 CN disclosed
EP-3710444-B1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-04-12 EP disclosed
US-10995085-B2 Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors MERCK SHARP & DOHME CORP. (US) 2021-05-04 US disclosed
US-20200216425-A1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2020-07-09 US disclosed
EP-2086961-A1 HETEROCYCLIC DERIVATIVES AS CETP INHIBITORS Novartis AG (CH) 2009-08-12 EP disclosed
EP-2084149-A1 ORGANIC COMPOUNDS Novartis AG (CH) 2009-08-05 EP disclosed
US-20090075968-A1 CETP inhibitors SAKAKI JUNICHI 2009-03-19 US disclosed
US-20090075968-A1 CETP inhibitors SAKAKI JUNICHI 2009-03-19 US disclosed
US-20090075968-A1 CETP inhibitors SAKAKI JUNICHI 2009-03-19 US disclosed
EP-1968941-A1 PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) Novartis AG (CH) 2008-09-17 EP disclosed
WO-2008058961-A1 HETEROCYCLIC DERIVATIVES AS CETP INHIBITORS NOVARTIS AG (CH) 2008-05-22 WO disclosed
WO-2008058967-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2008-05-22 WO disclosed
WO-2007073934-A1 PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) NOVARTIS AG (CH) 2007-07-05 WO disclosed
WO-2007073934-A1 PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) NOVARTIS AG (CH) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216425-A1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS IDO1, IDO2, KYNU LMNA 4606/4885KMT2A 731/4885ALDH1A1 516/4885
US-10995085-B2 Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors IDO1, IDO2, KYNU LMNA 4600/4885KMT2A 753/4885ALDH1A1 535/4885
US-20240166664-A1 TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WEE1, WEE2 LMNA 563/4885KMT2A 2349/4885ALDH1A1 1500/4885
US-20090075968-A1 CETP inhibitors CETP, PCSK9, MTTP LMNA 1663/4885KMT2A 1987/4885ALDH1A1 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.